Details for New Drug Application (NDA): 209450
✉ Email this page to a colleague
The generic ingredient in LUBIPROSTONE is lubiprostone. There are ten drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.
Summary for 209450
| Tradename: | LUBIPROSTONE |
| Applicant: | Amneal |
| Ingredient: | lubiprostone |
| Patents: | 0 |
Pharmacology for NDA: 209450
| Mechanism of Action | Chloride Channel Activators |
Medical Subject Heading (MeSH) Categories for 209450
Suppliers and Packaging for NDA: 209450
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209450 | ANDA | AvKARE | 42291-475 | 42291-475-60 | 60 CAPSULE in 1 BOTTLE (42291-475-60) |
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209450 | ANDA | AvKARE | 42291-476 | 42291-476-60 | 60 CAPSULE in 1 BOTTLE (42291-476-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 8MCG | ||||
| Approval Date: | Nov 30, 2021 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 24MCG | ||||
| Approval Date: | Nov 30, 2021 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
